Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Chuo, TokyoFounded 20054,105 employeesWebsite
A leading Japanese R&D-driven pharmaceutical company with a global presence, specializing in oncology, urology, and transplant medicine.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| XTANDI Product Business | 77% | ¥960.8B | ¥0 | 0.0% |
| PADCEV Product Business | 18% | ¥221.2B | ¥0 | 0.0% |
| VYLOY Product Business | 5% | ¥63.1B | ¥0 | 0.0% |
Close (Oct 30, 2026)
¥2,571+63.2% (1Y)
Astellas +63.2% over 1Y, 52.4pt above the industry average (23 companies, +10.7%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥2.1T | ¥382.6B | ¥291.5B | ¥3.6T | +11.9% |
| 2025FY | ¥1.9T | ¥41.0B | ¥50.7B | ¥3.3T | +19.2% |
| 2024FY | ¥1.6T | ¥25.5B | ¥17.0B | ¥3.6T | +5.6% |
| 2023FY | ¥1.5T | ¥133.0B | ¥98.7B | ¥2.5T | +17.2% |
| 2022FY | ¥1.3T | ¥155.7B | ¥124.1B | ¥2.3T | +3.7% |
| 2021FY | ¥1.2T | ¥136.1B | ¥120.6B | ¥2.3T | — |
Sources: annual securities reports, earnings releases and other public disclosures (Dec 2024)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
